Plant Name: Fritillaria taipaiensis
Taxonomic Information:
Plant ID: NPO25808
Plant Latin Name: Fritillaria taipaiensis
Taxonomy Genus: Fritillaria
Taxonomy Family: Liliaceae
Plant External Links:
NCBI TaxonomyDB:
152093
Plant-of-the-World-Online:
535333-1
Used in Medicines:
Unknown.
Geographical Distribution:
China
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADORA3; ADORA2A; ADORA1; | |
| CDA; RECQL; TK1; ADK; HSD17B10; ALDH1A1; HPGD; PNP; | |
| NR1H4; | |
| CASP7; CASP1; | |
| STAT6; | |
| SLC28A2; SLC28A1; SLC28A3; | |
| SMN1;SMN2; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Enzyme_unclassified | CDA | Cytidine deaminase | P32320 | CHEMBL4502 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TK1 | Thymidine kinase, cytosolic | P04183 | CHEMBL2883 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | PNP | Purine nucleoside phosphorylase | P00491 | CHEMBL4338 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
| SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
| SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 3.865E-08 | 1.683E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 9.264E-08 | 2.521E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 1.126E-06 | 2.043E-03 | SLC28A2, SLC28A3 |
| MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 1.126E-06 | 2.043E-03 | SLC28A1, SLC28A3 |
| MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 1.126E-06 | 2.043E-03 | SLC28A2, SLC28A3 |
| BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 3.375E-06 | 3.868E-03 | SLC28A1, SLC28A3 |
| BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 3.375E-06 | 3.868E-03 | SLC28A1, SLC28A3 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 3.375E-06 | 3.868E-03 | ADORA1, ADORA2A |
| BP | GO:0008152; metabolic process | GO:0044281; small molecule metabolic process | 3.745E-05 | 2.374E-02 | ADK, ADORA2A, ALDH1A1, CDA, HPGD, HSD17B10, NR1H4, PNP, TK1 |
| CC | GO:0044456; synapse part | GO:0099055; integral component of postsynaptic membrane | 4.034E-05 | 2.374E-02 | ADORA1, ADORA2A |
| CC | GO:0043226; organelle | GO:0097504; Gemini of coiled bodies | 7.381E-05 | 3.653E-02 | SMN1, SMN2 |
| MF | GO:0003824; catalytic activity | GO:0097200; cysteine-type endopeptidase activity involved in execution phase of apoptosis | 8.718E-05 | 4.127E-02 | CASP1, CASP7 |
| CC | GO:0032991; macromolecular complex | GO:0032797; SMN complex | 8.718E-05 | 4.127E-02 | SMN1, SMN2 |
| MF | GO:0003824; catalytic activity | GO:0019206; nucleoside kinase activity | 1.016E-04 | 4.611E-02 | ADK, TK1 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09104 Nucleotide metabolism | hsa00240 | Pyrimidine metabolism | 1.746E-04 | 6.808E-03 | CDA, PNP, TK1 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.352E-03 | 1.470E-02 | CDA, PNP, ALDH1A1, ADK, TK1, HSD17B10 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00983 | Drug metabolism - other enzymes | 1.057E-03 | 1.470E-02 | CDA, TK1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05134 | Legionellosis | 1.508E-03 | 1.470E-02 | CASP7, CASP1 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 2.906E-03 | 1.889E-02 | ADORA2A, ADORA3, ADORA1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05133 | Pertussis | 2.782E-03 | 1.889E-02 | CASP7, CASP1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 9.364E-03 | 4.565E-02 | CASP7, LMNA |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 6.959E-03 | 3.877E-02 | ADORA3, ADORA1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 1.311E-02 | 4.709E-02 | ADORA3, ADORA1 |
| 09120 Genetic Information Processing | 09122 Translation | hsa03013 | RNA transport | 1.387E-02 | 4.709E-02 | SMN2, SMN1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TK1; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADORA2A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK; |
| NA: NA | Hepatitis C virus infection | NA | ADORA3; |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADORA2A; ADK; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ADORA1; ADORA2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADORA1; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3; |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TK1; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TK1; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1; |
| A00-B99: Certain infectious and parasitic diseases | Adult varicella zoster virus infection | B02 | TK1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | TK1; ADORA3; |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1; |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TK1; CDA; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADORA1; ADORA2A; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; |
| C00-D49: Neoplasms | Prostate cancer | C61 | TK1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Graft-versus-host disease | T86.0 | TK1; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA1; ADORA2A; ADORA3; |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA1; ADORA2A; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA1; ADORA2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADORA1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
